Arkolith/Insider Trading/AVTX/Form 4

Doyle Mittie

Chief Medical OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Jun 25, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$26K
Net Open-Market Flow
-$26K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 23, 2026Option exercise(M)1K$8.04$12K53K
Jun 23, 2026Sell(S)1K$18.00$26K52K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 23, 2026Option exercise(M)1K—$0117K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001918845-26-000020) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML